RD3, I am very serious for the following reasons.
Hi Tech trading at $43.09 which = 130.57 X last quarter’s EPS of $0.33.
Lannett trading at $24.99 which = 199.92 X last quarter’s EPS of $0.12
Impax. trading at $20.30 which = 290 X last quarter’s EPS of $0.07
Akorn trading at $20.89 which = 189.82 X last quarter’s EPS of $0.11
Hospira trading at $40.43 which = 202.15 X last quarter’s EPS of $0.20
Perrigo trading at $128.62 which = 102.08 X last quarter’s EPS of $1.26
Mylan trading at $38.41 which = 85.36 X last quarter’s EPS of $0.45
Excluding the highest and lowest multipliers of the group, the remaining pharmaceuticals trade on average at 164.9 x their last quarter EPS.
If ANI gets treated accordingly and comes in with an EPS of $0.15 to $0.20 they should be trading at $24.73 to $32.98
Now with the possibility of Teva selling Tesneo in January, 2014 and Teva being known for their aggressive marketing , sales of $200 million are not unreasonable. If this were the case ANI gets $10 million per year in royalties. That will add approx. $0.26 to ANI’s quarterly EPS. That works out to another $42.87 to the share price.
So yes, $70 by May, 2014 (post Q1 earnings) is very possible.
Market Data 
Markets 
